MediGene AG Appoints Dr. Frank Mathias as new Chief Executive Officer

05-May-2009 - Germany

MediGene AG announced that Dr. Peter Heinrich, Chief Executive Officer, has resigned from his position as member of the Executive Board with immediate effect. The Supervisory Board has accepted the resignation with great regret.

"On behalf of the MediGene Supervisory Board, I would like to thank Dr Peter Heinrich for his long time and successful leadership as Chief Executive Officer of the company. As a co-founder, he essentially shaped the company from the beginning. Due to his entrepreneurial achievements, MediGene today is an internationally acknowledged biotech company with subsidiaries in the UK and the USA and is listed in the German stock index TecDAX. The supervisory Board expresses its heartfelt thankfulness for his achievements and wishes him all the best for his future path of life", says Prof Dr Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene AG.

As successor, Dr. Frank Mathias has been appointed by the Supervisory Board. He has joined MediGene a year ago as Chief Operating Officer and Executive Board Member for Marketing, Sales and Business Development and has been responsible for the ongoing partnering process for the cancer drug candidate EndoTAG-1. The pharmacist with PhD has around 20 years' experience in the pharma and biotech industry, among others as General Manager of Amgen GmbH, subsidiary of Amgen Inc.

Dr. Mathias studied pharmacy at Paris VI University, taking his PhD in 1991. He embarked on his career in industry in 1988 as International Product Manager with Hoechst AG, Frankfurt, then in 1990 joined Albert-Roussel Pharma GmbH in Wiesbaden, first as a Pharmaceuticals Officer, then as a Product Group Manager and as Deputy Head of Marketing. In 1995 Dr. Mathias launched the Anti-Infectives Marketing Department at Hoechst Pharma in Frankfurt before moving as Head of Marketing to Servier Deutschland GmbH in Munich and taking over as General Manager there in 1996. In 2002 he moved as Head of Marketing to Amgen GmbH, Munich, the company he led successfully as General Manager since 2003. In April 2008, he joined the Executive Board of MediGene AG.

https://www.bionity.com/en/news/100447/medigene-ag-appoints-dr-frank-mathias-as-new-chief-executive-officer.html